Behavioral health data science and technology company Holmusk has announced a $45 million Series B financing round to accelerate the growth of its behavioral health data platform, the NeuroBlu Database. This flagship platform is designed to provide real-world behavioral health data, offering insights that can improve treatment outcomes, inform research, and guide policy decisions.
Series B Led by Veradigm with Data Contribution
The funding round was led by Veradigm Inc. (NASDAQ: MDRX), formerly Allscripts Healthcare Solutions Inc., which also plans to contribute de-identified behavioral health and related patient data to Holmusk’s behavioral health data platform. While the exact scale of the contribution has not been disclosed, Veradigm described it as significantly enhancing Holmusk’s real-world clinical data assets. By combining capital investment with new data, Holmusk is positioned to further expand its reach in the behavioral health sector.
Investor Participation and Funding History
Existing investors—including Heritas Capital, Health Catalyst Capital, dRx Capital, and Northwell Holdings—also participated in the Series B round. Holmusk’s fundraising history demonstrates steady investor confidence, following a $21.5 million Series A in May 2020 and a subsequent investment in December 2021 from Northwell Holdings, Optum Ventures, Health Catalyst Capital, and Heritas Capital.
CEO Statement on Expanding the Platform
Nawal Roy, founder and CEO of Holmusk, emphasized the importance of high-quality data in driving better behavioral health outcomes: “This investment will enable our team to continue its work in curating and enhancing data as we plan to build the world’s largest behavioral health data platform. We remain laser-focused on this mission because we know that quality data leads to improved evidence, which leads to better health outcomes.”
Strategic Partnerships to Improve Care Outcomes
Holmusk has also forged strategic partnerships to leverage its behavioral health data platform for real-world applications. In February, the company partnered with Metrocare Services, the largest provider of mental health and developmental disability services in North Texas, to develop tools aimed at improving care outcomes. These collaborations highlight Holmusk’s commitment to translating data insights into actionable solutions for clinicians and healthcare organizations.
Veradigm’s Role and Industry Perspective
Rick Poulton, CEO of Veradigm, stated, “Mental and behavioral health is a serious global health problem that has only increased during and post the COVID-19 pandemic. Holmusk has proven expertise to create the evidence needed to improve mental health.” Veradigm, which serves the biopharma, health insurance, and health system sectors, recognizes the value of a robust behavioral health data platform in supporting research and treatment innovation.
Behavioral Health Investment Landscape
Investment in behavioral health technology continues, though at a slower pace compared to the peak funding levels of 2021. Recent rounds include Array Behavioral Care, which raised $25 million led by CVS Health Ventures, and youth-focused mental health technology companies like Vita Health, raising $8.4 million, and Vanna Health, raising $29 million ahead of its official launch. Holmusk’s Series B round reinforces the ongoing investor interest in technology-driven solutions for serious mental illness (SMI) and behavioral health care.
NeuroBlu Database as a Data-Driven Solution
Holmusk’s behavioral health data platform is designed to provide clinicians, researchers, and healthcare organizations with actionable insights derived from real-world patient data. By combining this funding with new strategic partnerships, Holmusk aims to expand its ability to curate, analyze, and interpret complex behavioral health information. These efforts are critical in an era where data-driven decision-making can directly impact patient care and outcomes.
Bridging Gaps in Behavioral Health Care
As the behavioral health sector faces rising demand for services and workforce shortages, platforms like NeuroBlu offer scalable solutions for understanding patient needs and improving care. Holmusk’s behavioral health data platform bridges gaps in research and treatment, enabling evidence-based approaches that can enhance both clinical practice and population health initiatives.
Global Vision and Future Plans
With this latest funding and strategic data partnerships, Holmusk is positioned to become a global leader in behavioral health technology. The behavioral health data platform continues to serve as a cornerstone for real-world evidence generation, demonstrating how quality data can lead to better outcomes, more informed policies, and improved access to mental health services worldwide. In the coming years, Holmusk aims to expand its behavioral health data platform globally, providing researchers, clinicians, and healthcare organizations with the tools needed to harness real-world data.
